Axcella Health (AXLA) Competitors

Axcella Health is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

65.1% of Axcella Health shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 2.2% of Axcella Health shares are held by insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Axcella Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, indicating that its stock price is 190,833% less volatile than the S&P 500.

In the previous week, Axcella Health's average media sentiment score of 0.00 equaled Eloxx Pharmaceuticals'average media sentiment score.

Axcella Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

In the previous week, Axcella Health's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

65.1% of Axcella Health shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 2.2% of Axcella Health shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Axcella Health has higher earnings, but lower revenue than Sorrento Therapeutics. Axcella Health is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Axcella Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

In the previous week, Axcella Health's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Axcella Health's return on equity of 0.00% beat Genocea Biosciences' return on equity.

65.1% of Axcella Health shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 2.2% of Axcella Health shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genocea Biosciences has higher revenue and earnings than Axcella Health. Axcella Health is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

65.1% of Axcella Health shares are owned by institutional investors. 2.2% of Axcella Health shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Axcella Health's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Axcella Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500.